Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Definity Vial for (Perflutren Lipid Microsphere) Injectable Suspension

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – October 2011

 

Summary View

 

BOXED WARNING

  • Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration [see WARNINGS AND PRECAUTIONS (5.1)]. Most serious reactions occur within 30 minutes of administration.....

 

WARNINGS AND PRECAUTIONS

Serious Cardiopulmonary Reactions, and:
 
Anaphylactoid Reactions:
  • minor changes in both sections.....

 

ADVERSE REACTIONS

Postmarketing Experience
  • Reported reactions included: ......

 

USE IN SPECIAL POPULATIONS

Geriatric Use
  • In clinical trials, the overall incidence of adverse reactions was similar for the <65 year age group and the ≥65 year age group. Of the total .....
-
-